4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been given an average recommendation of “Moderate Buy” by the ten research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $33.25.

A number of brokerages have commented on FDMT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st. Chardan Capital restated a “buy” rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, December 18th. Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Barclays initiated coverage on 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 price target on the stock. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 7th.

4D Molecular Therapeutics Stock Performance

4D Molecular Therapeutics stock opened at $9.66 on Monday. The firm has a market cap of $551.88 million, a price-to-earnings ratio of -2.58 and a beta of 2.99. 4D Molecular Therapeutics has a 52-week low of $2.23 and a 52-week high of $12.34. The firm has a 50 day moving average price of $8.47 and a two-hundred day moving average price of $8.93.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd acquired a new position in shares of 4D Molecular Therapeutics during the first quarter worth approximately $39,000. Wexford Capital LP purchased a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter valued at $41,000. Los Angeles Capital Management LLC bought a new stake in 4D Molecular Therapeutics in the second quarter worth about $42,000. Quadrature Capital Ltd bought a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter worth approximately $42,000. Finally, Farther Finance Advisors LLC lifted its position in shares of 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after buying an additional 2,674 shares during the last quarter. Institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.